VAERS Explorer
Back to explore

Report #2864112

Received Oct 7, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
0.1 yrs
State
IN
Recovered
Unknown
Vaccinated
Sep 29, 2025
Onset
Sep 29, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
FLU3INFLUENZA (SEASONAL) (FLUZONE)SANOFI PASTEURUNKU8827AAOT

Symptoms (2)

No adverse eventProduct administered to patient of inappropriate age

Symptom narrative

6-week-old patient received the FLUZONE TRI in error with no reported adverse event; Initial information received on 02-Oct-2025 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 6 weeks old female patient who received the Influenza Quadrival A-B Multidose Vaccine Preserved [Fluzone] in error with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Hepatitis b vaccine (Hepatitis b), Pneumococcal vaccine (Pneumococcal vaccine), Diphtheria vaccine toxoid, HIB vaccine conj (tet tox), Pertussis vaccine acellular 5-component, Polio vaccine inact 3v (MRC 5), Tetanus vaccine toxoid (Pentacel) and Rotavirus vaccine (Rotavirus vaccine) for Immunisation. On 29-Sep-2025, the patient received 0.5mL of suspect Influenza Quadrival A-B Multidose Vaccine Preserved, Suspension for injection (lot U8827AA, expiry date 30-Jun-2026, strength standard and frequency once) via intramuscular route in unknown administration site for prophylactic vaccination (Immunisation) and 6-week-old patient received the fluzone tri in error with no reported adverse event (product administered to patient of inappropriate age) (latency same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Other medications

Hepatitis b; Pneumococcal vaccine; Pentacel; Rotavirus vaccine